We are live on ! Find out more
APM

Avidity Partners Management Portfolio holdings

AUM $624M Turnover 44.83%
1-Year Est. Return 250.2%
This Fund
S&P 500
This Quarter Est. Return
+25.49%
1 Year Est. Return
+250.2%
3 Year Est. Return
+491.63%
5 Year Est. Return
+985.37%
10 Year Est. Return
–
AUM
$4.62B
AUM Growth
-$303M
Cap. Flow
-$726M
Cap. Flow %
-15.73%
Top 10 Hldgs %
43.33%
Holding
116
New
19
Increased
32
Reduced
19
Closed
31
Avg Time Held Equity + Options
0.8 years
Top 10 Avg Time Held Equity + Options
0.2 years
Top 20 Avg Time Held Equity + Options
0.4 years
Avg Time Held Equity only
0.8 years
Top 10 Avg Time Held Equity only
0.2 years
Top 20 Avg Time Held Equity only
0.4 years

Top Buys

Rank Stock Value
1
UHS icon
Universal Health Services
UHS
+$97.5M
2
SGRY icon
Surgery Partners
SGRY
+$75.3M
3
JAZZ icon
Jazz Pharmaceuticals
JAZZ
+$60M
4
PRTA icon
Prothena Corp
PRTA
+$57.7M
5
ARGX icon
argenx
ARGX
+$49.8M

Top Sells

Rank Stock Value
1
LLY icon
Eli Lilly
LLY
+$280M
2
BIIB icon
Biogen
BIIB
+$160M
3
XBI icon
State Street SPDR S&P Biotech ETF
XBI
+$120M
4
VRTX icon
Vertex Pharmaceuticals
VRTX
+$104M
5
HUM icon
Humana
HUM
+$103M

Sector Composition

Rank Sector Weight
1 Healthcare 92.28%
2 Miscellaneous 7.3%
3 Financials 0.42%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow Held Since
XBI icon
1
CALL
State Street SPDR S&P Biotech ETF
XBI
$9.9B
$337M 7.3%
+4,062,000
New +$329M
2022 Q4
0 quarters
ARGX icon
2
argenx
ARGX
$53.2B
$237M 5.13%
625,000
+133,200
+27% +$49.8M
2022 Q1
3 quarters
UTHR icon
3
United Therapeutics
UTHR
$23.2B
$218M 4.73%
785,500
-184,700
-19% -$46.6M
2021 Q2
6 quarters
NBIX icon
4
Neurocrine Biosciences
NBIX
$13.9B
$213M 4.61%
1,780,000
-75,700
-4% -$8.87M
2020 Q4
8 quarters
AKRO icon
5
DELISTED
Akero Therapeutics
AKRO
$210M 4.54%
3,825,000
+703,000
+23% +$30.1M
2022 Q3
1 quarter
PRTA icon
6
Prothena Corp
PRTA
$436M
$178M 3.85%
2,953,000
+986,000
+50% +$57.7M
2022 Q3
1 quarter
ARVN icon
7
Arvinas
ARVN
$468M
$169M 3.67%
4,950,000
+606,500
+14% +$25.5M
2020 Q2
10 quarters
BSX icon
8
Boston Scientific
BSX
$64B
$151M 3.26%
3,256,700
+718,100
+28% +$31.1M
2022 Q1
3 quarters
SNDX icon
9
Syndax Pharmaceuticals
SNDX
$1.22B
$149M 3.23%
5,861,000
+274,100
+5% +$6.39M
2020 Q2
10 quarters
RARE icon
10
Ultragenyx Pharmaceutical
RARE
$1.5B
$139M 3%
2,990,000
+938,400
+46% +$36.9M
2021 Q3
5 quarters
SRPT icon
11
Sarepta Therapeutics
SRPT
$1.88B
$137M 2.96%
1,055,000
+106,800
+11% +$12.4M
2022 Q3
1 quarter
MDGL icon
12
Madrigal Pharmaceuticals
MDGL
$10.6B
$125M 2.7%
+430,000
New +$42.1M
2022 Q4
0 quarters
UHS icon
13
Universal Health Services
UHS
$11B
$116M 2.52%
+825,600
New +$97.5M
2022 Q4
0 quarters
JAZZ icon
14
Jazz Pharmaceuticals
JAZZ
$13.9B
$116M 2.51%
727,541
+409,241
+129% +$60M
2022 Q2
2 quarters
ZNTL icon
15
Zentalis Pharmaceuticals
ZNTL
$212M
$104M 2.25%
5,150,000
+926,900
+22% +$19.9M
2020 Q2
10 quarters
ACHC icon
16
Acadia Healthcare
ACHC
$2.89B
$95.9M 2.08%
1,165,000
-224,200
-16% -$18.5M
2022 Q2
2 quarters
SGRY icon
17
Surgery Partners
SGRY
$1.93B
$86.7M 1.88%
3,112,000
+2,844,400
+1,063% +$75.3M
2022 Q3
1 quarter
DXCM icon
18
DexCom
DXCM
$33.1B
$85.7M 1.86%
756,800
+289,200
+62% +$31.8M
2022 Q3
1 quarter
AZN icon
19
AstraZeneca
AZN
$259B
$81.4M 1.76%
600,000
+318,400
+113% +$39.9M
2021 Q3
5 quarters
LLY icon
20
Eli Lilly
LLY
$1.12T
$79.4M 1.72%
217,000
-790,000
-78% -$280M
2022 Q2
2 quarters
PCVX icon
21
Vaxcyte
PCVX
$10.3B
$77.5M 1.68%
1,615,400
+986,700
+157% +$38.7M
2022 Q3
1 quarter
RNAM
22
DELISTED
Avidity Biosciences
RNAM
$72.7M 1.57%
3,275,000
+675,000
+26% +$10.1M
2021 Q3
5 quarters
NTRA icon
23
Natera
NTRA
$58.3B
$72.3M 1.57%
1,798,900
+63,900
+4% +$2.63M
2020 Q3
9 quarters
IDYA icon
24
IDEAYA Biosciences
IDYA
$3.27B
$69.5M 1.51%
3,824,800
+109,400
+3% +$1.84M
2021 Q1
7 quarters
IMCR icon
25
Immunocore
IMCR
$1.52B
$65.9M 1.43%
1,154,000
-925,100
-44% -$52.1M
2021 Q1
7 quarters
1
2 3 4 5

Similar funds

ANB
Amarillo National Bank Amarillo, Texas $624M AUM 20.28% 1-Year Est. Return
CWM
Chemistry Wealth Management New York $625M AUM 19.32% 1-Year Est. Return
RIP
RAM Investment Partners Bellevue, Washington $625M AUM 16.29% 1-Year Est. Return
TAM
Third Avenue Management New York $625M AUM 48.93% 1-Year Est. Return
B
Bellecapital Zurich, Switzerland $625M AUM 39.69% 1-Year Est. Return
PWS
Proactive Wealth Strategies Marietta, Georgia $623M AUM 30.7% 1-Year Est. Return
LWP
LMG Wealth Partners Shreveport, Louisiana $626M AUM 36.27% 1-Year Est. Return
TAA
TB Alternative Assets Grand Cayman, Cayman Islands $623M AUM 154.99% 1-Year Est. Return

Avidity Partners Management's Q4 2022 Portfolio in Review

As of Q4 2022, Avidity Partners Management held 116 positions worth $4.62B, down 6.2% from $4.92B the previous quarter. Its ten largest holdings account for 43% of the portfolio.

Avidity Partners Management withdrew a net $726M in Q4 2022, closing 31 positions and reducing 19 holdings. Its most notable exit was Biogen, an estimated $160M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 92% of assets, up from 91% a quarter earlier, followed by Miscellaneous and Financials.

Against the trend, Avidity Partners Management opened a new position in Universal Health Services worth $116M.

  • Avidity Partners Management's largest Q4 2022 buy was Universal Health Services: 825,600 shares worth $116M.
  • Avidity Partners Management added most to Surgery Partners in Q4 2022, an estimated $75.3M increase.
  • Avidity Partners Management's biggest Q4 2022 reduction was Eli Lilly, cutting an estimated $280M.
  • Avidity Partners Management fully exited Biogen in Q4 2022, selling an estimated $160M.
  • Avidity Partners Management's ten largest holdings make up 43% of its $4.62B portfolio in Q4 2022.
  • Avidity Partners Management opened 19 new positions and closed 31 in Q4 2022.
  • Avidity Partners Management's portfolio value fell 6.2% quarter-over-quarter to $4.62B.

Based on Avidity Partners Management's 13F filing for Q4 2022, filed 14 Feb 2023.